| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12013-011-9257-6 |
| P698 | PubMed publication ID | 21910030 |
| P2093 | author name string | Binbin Cui | |
| Yanmei Yang | |||
| Ji Tao | |||
| P2860 | cites work | Weakening link to colorectal cancer? | Q57006460 |
| Essential role for the p110 isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia | Q57220263 | ||
| Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential | Q24329100 | ||
| PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies | Q27851465 | ||
| The phosphoinositide 3-kinase pathway | Q27860738 | ||
| Essential role for the p110delta phosphoinositide 3-kinase in the allergic response | Q28288981 | ||
| Cancer statistics, 2009 | Q29547625 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| The emerging mechanisms of isoform-specific PI3K signalling | Q29617954 | ||
| Effective surgical adjuvant therapy for high-risk rectal carcinoma | Q33387384 | ||
| Rules for making human tumor cells | Q34159004 | ||
| The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells | Q34234737 | ||
| Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase | Q34335162 | ||
| Cancer-specific mutations in PIK3CA are oncogenic in vivo | Q34335169 | ||
| The PTEN-PI3K pathway: of feedbacks and cross-talks | Q34828662 | ||
| Phosphoinositide 3-kinase signalling--which way to target? | Q35181798 | ||
| Oncogenic PI3K deregulates transcription and translation | Q36337966 | ||
| The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. | Q36751486 | ||
| PTEN-deficient cancers depend on PIK3CB. | Q36861839 | ||
| PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer | Q37137091 | ||
| Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT? | Q37145834 | ||
| Drug discovery approaches targeting the PI3K/Akt pathway in cancer | Q37270455 | ||
| Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase | Q38326223 | ||
| Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors | Q39747551 | ||
| Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. | Q40012035 | ||
| Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. | Q41791633 | ||
| Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach | Q42191925 | ||
| Functional analysis of PIK3CA gene mutations in human colorectal cancer | Q42814030 | ||
| A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells | Q42834760 | ||
| Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. | Q42948871 | ||
| Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer | Q43280944 | ||
| BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. | Q46807683 | ||
| Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)Kgamma | Q47832177 | ||
| Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? | Q51704738 | ||
| Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers | Q51717752 | ||
| PI3K regulatory subunits lose control in cancer. | Q54705697 | ||
| Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. | Q55471652 | ||
| P433 | issue | 1 | |
| P921 | main subject | colorectal cancer | Q188874 |
| P304 | page(s) | 47-54 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Cell Biochemistry and Biophysics | Q15755135 |
| P1476 | title | Studies on the expression patterns of class I PI3K catalytic subunits and its prognostic significance in colorectal cancer | |
| P478 | volume | 62 |
| Q54397311 | Abelson interactor 1 (Abi1) in colorectal cancer. From synaptic plasticity to tumor cell migration |
| Q57024518 | Biochemical significance of limonene and its metabolites: future prospects for designing and developing highly potent anticancer drugs |
| Q54188074 | Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer |
| Q44123472 | Expression and clinicopathological significance of Mel-18 mRNA in colorectal cancer |
| Q50047956 | Hypoxia induces pulmonary arterial fibroblast proliferation, migration, differentiation and vascular remodeling via the PI3K/Akt/p70S6K signaling pathway |
| Q53136255 | Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells |
| Q34732954 | PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma |
| Q38805492 | PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma |
| Q34552147 | Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma |
| Q33776641 | Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development |
Search more.